Intellia Therapeutics, Inc (NTLA)
Health Care – IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
- Headquarters
- United States
- Employees
- 377
- Market Cap
- $1.6B
About Intellia Therapeutics, Inc
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
SentiSense also tracks daily options readings for Intellia Therapeutics, Inc: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Intellia Therapeutics, Inc stock analysis, sentiment tracking, and market intelligence on SentiSense.